Ginkgo Bioworks Holdings, Inc.(DNA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,800 of 2,960 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
DNA Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Ginkgo Bioworks Holdings, Inc. (DNA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DNA at 18.8/100 on a 32-signal composite quality model, placing it at rank #2,800 of 2,960 stocks — the bottom half of the AI-ranked universe. DNA scores in the top quartile across institutional flow (94.3). Areas of concern include revenue growth (2.7) and profitability (5.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Ginkgo Bioworks Holdings, Inc. reports quarterly revenue of $20.2M, net income of $-46.7M, free cash flow of $-46.9M. Top institutional holders of DNA by reported 13-F value include BlackRock, VIKING GLOBAL INVESTORS, Erste Asset Management GmbH, based on the most recent SEC filings. DNA trades on the NYSE exchange and files with the SEC under CIK 1830214. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DNA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Ginkgo Bioworks Holdings, Inc. directly from SEC EDGAR. Ginkgo Bioworks Holdings, Inc.'s 13F Pro composite quality score has ranged between 12 and 43 since 2021, currently 18.8 — a declining long-term trajectory across 65 quarterly and live scoring snapshots.
Revenue
Q2 2026
$20.2M
Net Income
Q2 2026
$-46.7M
Free Cash Flow
Q2 2026
$-46.9M
ROIC
Q2 2026
-55.7%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-25.1% YoYNet Income
+42.8% YoYOperating Income
+43.7% YoYEPS (Diluted)
+46.5% YoYTotal Assets
-18.7% YoYOp. Cash Flow
+46.5% YoYFree Cash Flow
+53.2% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $170.2M -25.1% | $227.0M -9.7% | $251.5M -47.4% | $477.7M +52.2% | $313.8M +309.4% | $76.7M |
| Net Income | $-312.8M +42.8% | $-547.0M +38.7% | $-892.9M +57.6% | $-2.10B -15.0% | $-1.83B -1345.4% | $-126.6M |
| Operating Income | $-315.3M +43.7% | $-559.8M +35.2% | $-864.4M +60.9% | $-2.21B -20.8% | $-1.83B -1234.4% | $-137.0M |
| EPS (Diluted) | $-5.64 +46.5% | $-10.54 +42.6% | $-18.37 +63.4% | $-50.20 -3511.5% | $-1.39 -1290.0% | $-0.10 |
| Total Assets | $1.12B -18.7% | $1.38B -17.3% | $1.67B -34.4% | $2.54B +22.6% | $2.07B +206.7% | $675.2M |
| Operating Cash Flow | $-171.1M +46.5% | $-319.6M -8.2% | $-295.5M -17.2% | $-252.2M +0.6% | $-253.8M -86.9% | $-135.8M |
| Free Cash Flow | $-178.7M +53.2% | $-382.1M -13.6% | $-336.3M -10.5% | $-304.5M +1.9% | $-310.3M -60.3% | $-193.7M |
Get alerted when DNA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Ginkgo Bioworks Holdings, Inc. including:
Top Institutional Holders of DNA
BlackRock, Inc.
$42.4M4,282,903 shVIKING GLOBAL INVESTORS LP
$35.4M3,577,128 shErste Asset Management GmbH
$25.9M2,536,939 shBAILLIE GIFFORD & CO
$23.7M2,391,649 shVANGUARD CAPITAL MANAGEMENT LLC
$20.7M2,087,293 shAnchorage Capital Group, L.L.C.
$17.3M1,746,363 shLegal & General Group Plc
$16.5M1,669,419 shSTATE STREET CORP
$14.6M1,472,370 shGEODE CAPITAL MANAGEMENT, LLC
$12.1M1,222,016 shFORBES J M & CO LLP
$9.9M999,911 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $42.4M | 4,282,903 |
| VIKING GLOBAL INVESTORS LP | $35.4M | 3,577,128 |
| Erste Asset Management GmbH | $25.9M | 2,536,939 |
| BAILLIE GIFFORD & CO | $23.7M | 2,391,649 |
| VANGUARD CAPITAL MANAGEMENT LLC | $20.7M | 2,087,293 |
| Anchorage Capital Group, L.L.C. | $17.3M | 1,746,363 |
| Legal & General Group Plc | $16.5M | 1,669,419 |
| STATE STREET CORP | $14.6M | 1,472,370 |
| GEODE CAPITAL MANAGEMENT, LLC | $12.1M | 1,222,016 |
| FORBES J M & CO LLP | $9.9M | 999,911 |
Companies Similar to DNA
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Caribou Biosciences, Inc.
RECURSION PHARMACEUTICALS, INC.
MARAVAI LIFESCIENCES HOLDINGS, INC.
NEKTAR THERAPEUTICS
Relay Therapeutics, Inc.
Maze Therapeutics, Inc.
C4 Therapeutics, Inc.
Intellia Therapeutics, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put DNA on your watchlist
Track score changes the day Ginkgo Bioworks Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is DNA a good stock to buy?
13F Pro's AI-powered analysis of Ginkgo Bioworks Holdings, Inc. (DNA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DNA are available on the DNA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. DNA is classified as a small company.
Which hedge funds own DNA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DNA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Ginkgo Bioworks Holdings, Inc.'s investment landscape.